ProImmune Limited Publishes White Paper 'Managing Immunogenicity Risk Through Assay-based Rational Drug Design and Selection'

Published: Nov 23, 2011

OXFORD, England--(BUSINESS WIRE)--ProImmune Ltd., a leader in services for understanding immune responses, has published a white paper on the effective management of immunogenicity risk in the design of biologics. The document addresses issues including how to manage immunogenicity effectively, improvement of drugs through better rational design methods, and what can be learned from measuring T cell responses at the preclinical stage.

Back to news